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Summary
The incidence of mixed genotype hepatitis C virus (HCV) infections in the UK is largely 
unknown. As the efficacy of direct- acting antivirals is variable across different geno-
types, treatment regimens are tailored to the infecting genotype, which may pose is-
sues for the treatment of underlying genotypes within undiagnosed mixed genotype 
HCV infections. There is therefore a need to accurately diagnose mixed genotype in-
fections prior to treatment. PCR- based diagnostic tools were developed to screen for 
the occurrence of mixed genotype infections caused by the most common UK geno-
types, 1a and 3, in a cohort of 506 individuals diagnosed with either of these geno-
types. The overall prevalence rate of mixed infection was 3.8%; however, this rate was 
unevenly distributed, with 6.7% of individuals diagnosed with genotype 3 harbouring 
genotype 1a strains and only 0.8% of samples from genotype 1a patients harbouring 
genotype 3 (P < .05). Mixed infection samples consisted of a major and a minor geno-
type, with the latter constituting less than 21% of the total viral load and, in 67% of 
cases, less than 1% of the viral load. Analysis of a subset of the cohort by Illumina PCR 
next- generation sequencing resulted in a much greater incidence rate than obtained 
by PCR. This may have occurred due to the nonquantitative nature of the technique 
and despite the designation of false- positive thresholds based on negative controls.
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1  | INTRODUCTION
The prevalence of mixed genotype HCV infections has been assessed 
across numerous geographical regions with broad estimates between 
1.2% and 25.3% being reported.1,2 Although some variability can be 
explained by study design differences, populations and detection 
methods, the numbers of mixed infection positive patients identi-
fied in studies are frequently too low to obtain meaningful statistical 
power.3 The incidence of mixed genotype HCV infections in larger 
studies is less than 8%.4-7 In the UK, only a relatively small study has 
been conducted which indicated prevalence rates of 9% and 19% in 
PWID and haemophiliacs, respectively.8 Many tests currently used in 
clinical settings lack the sensitivity and specificity required for diagno-
sis of mixed infection which are therefore rarely detected.5Abbreviations: DAA, direct acting antiviral; HCV, hepatitis C virus; NGS, next-generation se-
quencing; PWID, people who inject drugs; SVR, sustained virological response.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
© 2017 The Authors. Journal of Viral Hepatitis Published by John Wiley & Sons Ltd.
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DAA therapies for HCV infection have revolutionised treatment 
of the disease. These new drugs have been optimised for genotype 1 
(gt1), and SVR rates can be lower for other genotypes, particularly gt3. 
Consequently genotype- specific regimens may be required for effective 
treatment.9 The efficacy of DAAs against mixed genotype infections has 
yet to be determined although several studies have hypothesized that 
mixed infections may only be partially resolved by therapy regimens tai-
lored to the major infecting genotype, leading to genotype switching.10,11
Due to morbidity issues and cost implications of repeated DAA treat-
ments, improved diagnostics for mixed genotype infections to optimise 
treatment regimens are important. In this study, we sought to determine 
the prevalence of mixed HCV infection in a cohort of 506 HCV- positive 
patients from across Scotland. We focused on gt1a and gt3 which to-
gether constitute greater than 90% of the total HCV infections in the 
UK. Highly sensitive genotype- specific nested PCR assays were devel-
oped and used to screen for gt1a/gt3 mixed infections. The relative pro-
portion of each genotype within the mixed infections was determined 
by real- time (rt)- PCR. Furthermore, we compared the genotype- specific 
PCR techniques with NGS for diagnosis of mixed HCV infections.
2  | MATERIALS AND METHODS
2.1 | Patient cohort
Anonymised sera samples from 506 HCV- positive patients genotyped 
as 1a or 3 were obtained from the West of Scotland and Lothian 
Specialist Virology Centres. Samples were acquired during 2011, 
2013 and 2014. Ethical approval was granted by the NHS Research 
Scotland Greater Glasgow and Clyde Biorepository.
2.2 | Control transcripts
Control RNA transcripts derived from synthetic dsDNA based on a 
gt1a (H77, AF009606) and a gt3 (3a.GB.2005, GQ356206) sequence 
were used for PCR and rt- PCR optimisation, for relative quantification 
and as NGS fidelity controls.3,12-14
2.3 | RNA extraction and PCR
Viral RNA extracted from serum samples using a QIAamp viral RNA 
mini kit (Qiagen, Germantown, MD, USA) was transcribed into cDNA 
using SuperScript III reverse transcriptase (Thermo Fisher Scientific, 
Waltham, MA, USA). Nested PCR was performed using Platinum 
Taq (Thermo Fisher Scientific) and KOD Hot Start (Merk Millipore, 
Billerica, MA, USA) sequentially for 40 and 25 cycles, respectively. 
Primers used to screen for gt1a and gt3 strains (Table 1) were de-
signed using alignments of reference sequences from the Los Alamos 
HCV database.15 Screening reactions included a transcript of the ap-
propriate genotype (positive control) and a negative control consist-
ing of water replacing sample. Amplicons were treated with Illustra 
Exostar (VWR Int., Radnor, PA, USA) and Sanger- sequenced. Mock 
mixed infections consisting of gt1a and gt3a transcript control RNA 
Genotype 
specificity
Primer 
type Sequence Genome positiona
PCR
Gt1a OS CAT ATA ACG GGY CAY CGC ATG G 1275- 1296
OAS TGG TTY GGY TGY ACY TGG ATG AA 2008- 1986
IS ATG ATR ATG AAC TGG TCY CCY AC 1305- 1327
IAS TYG TCC TYA AYA ACA CYA GRC C 1972- 1951
Gt3 OS TTY CTY GTG GGR CAA GCC TTC A 1203- 1224
OAS CCT YTW CTG CCC CAC YGA CTG 2143- 2123
IS TTY AGA CCY CGY CGC CAT CA 1227- 1246
IAS CAG AYG TGT TCY TGC TGR AGT C 1993- 1972
Pan- genotypic S GC NTG GGA YAT GAT GAT GAA YTG 1296- 1318
AS GDG SGT ART GCC ARC ART ANG 1812- 1792
Real- time PCR
Gt1a S CTG TCG AGC CGC AGG GCT C 8507- 8525
AS GCT CCA AGT CGT AYT CTG GYT GBG 8686- 8662
Probe FAMTM- CCT CCG TGA AGG CTC TCA 
GGY TCG CYG CG- MGB
8625- 8597
Gt3 S GGA ACC CGG ACT TYC TYG TCT G 8527- 8548
AS CTC AAG GTC RTA GGT RGG CTG YGG 8684- 8661
Probe FAMTM- CGA CGC CRT CAC TCT CRG 
CCA CCA CRA CYA G- MGB
8589- 8559
O, outer; I, inner; S, sense; AS, antisense.
aGenome position is relative to the HCV strain H77 (Kuiken et al., 2006).
TABLE  1 Primers and probes designed 
for this study
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were assessed. These controls contained 25, 50 or 100 copies/μL of 
the minor strain with 106 copies/μL of the major genotype.
2.4 | Sequence analysis
Sequences were aligned using MUSCLE (v3.8) within SSE.16,17 
Maximum likelihood phylogenetic trees were produced using MEGA 
5.0.18 Bootstrap resampling (1000 replicates) was used to assess sta-
tistical support for tree branches, with bootstrap values ≥70% consid-
ered significant. Reference sequences were downloaded from NCBI 
Genbank and the Los Alamos HCV Database.19,20
2.5 | rt- PCR
rt- PCR was performed with the TaqMan fast 7500 system using 
TaqMan fast reagents (Thermo Fisher Scientific). An rt- PCR targeting 
the 5′ UTR was used to quantify the HCV viral load21 using a dilu-
tion series prepared from known concentrations of JFH- 1 replicon 
transcripts. Genotype- specific rt- PCR was performed using newly de-
signed primers and probes targeting the NS5B region (Table 1).
2.6 | Deep sequencing
In addition to the 19 mixed infection samples, 19 gt1a and 20 gt3 
randomly selected samples determined by PCR screening to be mono- 
infected also underwent deep sequencing. Mock mixed infections 
were prepared from gt1a and gt3a transcript control RNA consist-
ing of 103, 104 or 105 copies/μL of the minor strain with the major 
genotype to give a total of 106 copies/μL. Aliquots of single genotype 
transcripts (106 copies/μL) were used as fidelity controls, whereas 
HCV- negative serum and H2O provided negative controls. To limit 
contamination risk, samples were sequenced in two runs on the basis 
of genotype or major genotype.
Pan- genotypic PCR primers designed targeting partial E1- E2 region 
(Table 1) were modified by a phosphorothioate bond between the final 
two 3′ end nucleotides to render them resistant to 3′ to 5′ endonucle-
ase activity by proofreading enzymes. cDNA from screening reactions 
was amplified with the KAPA HiFi PCR kit (Sigma- Aldrich, Dorset, UK) 
for 30 cycles. Amplicons purified by Agencourt AMPure XP magnetic 
beads (Beckman Coulter, Pasadena, CA, USA) were quantified using the 
Qubit dsDNA High- Sensitivity kit (Thermo Fisher Scientific). Libraries 
prepared using the KAPA library preparation kit (Sigma- Aldrich) were 
analysed by TapeStation (Agilent Technologies, Santa Clara, CA, USA) to 
assess product size. Samples were pooled in equimolar ratios, and de-
natured libraries were run using the V3 MiSeq reagent kit (Illumina, San 
Diego, CA, USA) for 300 bp paired- end (p.e.) sequencing on a MiSeq 
Desktop Sequencer (Illumina). As diversity among samples was low, they 
were run at a relatively low cluster density with 5%- 10% PhiX controls.
2.7 | Deep sequencing analysis
Deep sequencing data were analysed using an in- house Unix- based 
pipeline. Low- quality reads were identified by FastQC and sequencing 
adapters removed using Trim Galore. An in- house bioinformatics pro-
gramme was developed for genotyping HCV using high- throughput 
sequences. This comparative genotype assignment method took 
37 bp k- mers from sequence reads and compared them against a list 
of reference genotype- specific k- mers of the same length. Although a 
longer k- mer could improve genotyping, they increase the risk of mis-
matches and require more computing power. Based on the breadth 
and depth of k- mer coverage, genotypes were assigned to samples. 
The best references to map sequence reads were selected based on 
the genotyping programme, and reads were mapped to reference 
genomes using Tanoti.22 Consensus sequences were generated and 
compared with Sanger- sequenced reads and reference genomes by 
phylogenetic analysis.
2.8 | Statistical analyses
Differences in the means and distributions of data were compared 
using the independent samples t test function. The significance of dif-
ferences in the distribution of categorical data was determined using 
Chi- squared tests.
3  | RESULTS
3.1 | Patient characteristics
Mixed gt1a/gt3 HCV infections were detected in samples collected 
from individuals residing throughout Scotland, indicating that no ge-
ographical region was particularly associated with mixed infections. 
The average age was comparable (P = .84) between individuals with 
mixed infections (40.6 ± 9.7 years) and mono- infected individuals 
(40.3 ± 9.3 years). The average viral load of mixed genotype infec-
tion samples was 5.78 ± 1.0 log10 IU/mL, similar (P = .61) to the av-
erage viral load observed in the cohort (5.63 ± 0.95 log10 IU/mL). 
Detailed clinical information was only available for patients resid-
ing within the Glasgow and Paisley postcode districts, accounting 
for 46.2% of the cohort. Within this group, 76.4% were male and 
a history of injecting drug use was recorded for 70.7% of subjects. 
Detailed clinical data were available for 4 individuals with mixed 
genotype infections. Liver disease was recorded for three of these 
subjects, two with cirrhosis and one with fibrosis. All four patients 
had a history of psychiatric disorders. Three of the patients had re-
ceived treatment for HCV infection (treatment type unknown) and 
of these, one had not yet completed treatment and two had failed 
to achieve an SVR.
3.2 | PCR analysis
PCR assay sensitivity was evaluated using known dilutions of the tran-
script controls tested in batches of 8 replicates with a negative control. 
Results were converted into probit values14,23 and using these values, 
a 90% detection rate of 9 (gt1a) and 21 (gt3) copies/μL of RNA were 
calculated. The specificity of the PCRs was confirmed by amplification 
and sequencing of the minor transcripts within mock mixed infections.
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A total of 506 patients diagnosed with gt1a or gt3 infec-
tion were screened for the presence of mixed gt1a/gt3 infection. 
Overall, 3.8% (19 of 506) of samples had a mixed gt1a/gt3 infec-
tion. Although 6.7% (17 of 252) of samples from gt3- diagnosed 
patients also contained gt1a, in the corresponding screen of gt1a 
samples, significantly fewer patients (P < .05) had an undiagnosed 
secondary gt3 infecting strain (0.8%, 2 of 253). The HCV strains 
involved in mixed gt1a/gt3 infections were dispersed throughout 
the phylogenetic trees (Figure 1) and were distinct from potential 
contaminants such as reference strains, other cohort strains and 
replicon strains cultured in nearby labs, thus confirming the pres-
ence of both genotypes. The average pairwise distances of the 
mixed genotype strains (gt1a, 0.176; gt3, 0.185) and strains from 
single genotype infections (gt1a, 0.182; gt3, 0.174) were compa-
rable. By analysing sequencing chromatograms, it was suspected 
that one sample (gt1a/gt3 sample G30) contained multiple gt1a 
strains. Clonal analysis revealed two distinct gt1a strains (G30- 2 to 
G30- 6 in Figure 1) in addition to the coinfecting gt3 strain. Mixed 
genotype samples G3- 80 and G3- 125 were from the same individ-
ual collected 1 month apart with the more recent sample (G3- 125) 
obtained during treatment with an unspecified antiviral regimen 
predating DAA introduction. Although the gt3 strains at the two 
time points were identical, the gt1a sequences differed substan-
tially (Figure 1).
3.3 | Quantification by rt- PCR
Genotype- specific rt- PCR assays were developed to quantify the rela-
tive proportions of gt1a and gt3 present in samples with mixed gen-
otypes. Consistent detection of less than 10 copies/μL of RNA was 
F I G U R E  1 Maximum likelihood phylogenetic trees of A, gt1a sequences (red) and B, gt3 sequences (blue) obtained from samples with mixed 
genotype HCV infections. Reference sequences are shown in black. Sequences obtained from individuals diagnosed with the opposite genotype 
are shown in boxes. Bootstrap support of >70% after 1000 replicates is shown
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observed for both gt1a and gt3 transcript controls whilst sample- free 
controls were negative.
All 20 mixed genotype samples were assayed by genotype- specific 
rt- PCR to determine individual viral loads, and positive rt- PCR results 
for both genotypes were obtained for 15 samples. In each sample, 
there was a major and a minor genotype, the latter constituting less 
than 21% of the combined viral load (Table 2) and in 10 of 15 samples 
constituting less than 1% of the combined viral load. Most (14 of 15) 
of the major genotypes have correlated with the clinical diagnosis of 
the patient. The exception was sample G3- 85 that was clinically diag-
nosed as a gt3 infection; however, the major genotype by rt- PCR was 
gt1a which constituted 99.6% of the combined viral load. In the re-
maining gt1a- diagnosed individuals with mixed infections (n = 2), the 
minor gt3 strains comprised 0.56% and 6.91% of the total viral load. 
In gt3- verified samples, the minor gt1a strains comprised 0.01%- 21% 
of the combined viral load. The limit of detection of the PCR assays for 
samples with mixed genotypes was less than 58 IU/mL.
3.4 | Analysis of mixed genotype infections by  
PCR- NGS
The pan- genotypic primers for the E1/E2 region (Table 1) were vali-
dated against an in- house panel of 64 previously typed HCV samples 
spanning nine subgenotypes from five genotypes (Table S1). These 
primers were subsequently used for the PCR- NGS amplification. 
Between 171 000 and 1 310 000 p.e., reads were produced from 
these samples of which 23 000- 825 765 mapped to the amplified 
HCV E1/E2 region (Table 3). The exceptions were sample G3- 71 (394 
p.e. reads, 83 E1/E2 reads) and the spike- in control Gt3- H (6 042 524 
p.e. reads, 2 276 655 E1/E2 reads). Suspected contamination was de-
tected in four samples, a gt2 strain closely related to HC- J6.D0094424 
and gt1a sequences related to H77 (>98% homology), both used lo-
cally in cell culture studies. No other genotypes or subgenotypes were 
detected by PCR- NGS.
The reads were normalised against the total number of E1/E2 
reads and expressed as a percentage. The percentages of normalised 
reads of the opposite genotype derived from the single genotype fi-
delity gt1a (gt3 < 0.002%) and gt3 (gt1a <0.007%) controls were low 
(Table 3). The serum negative controls, which were normalised against 
the total number of reads, also contained low levels of HCV E1/E2 
reads (<0.03%). Based on the false- positive figures from transcript 
and serum controls, a false- positive threshold of 0.019% of reads was 
calculated (average percentage of normalised reads + 2 × standard de-
viation). For samples identified as gt1a mono- infections by standard 
PCR, 2 of 19 (10.5%) contained gt3 reads above the false- positive rate, 
whereas 7 of 20 (35%) of the gt3 mono- infection samples contained 
gt1a reads. Gt3 major/gt1a minor infections were more abundant than 
gt1a major/gt3 minor infections, showing a trend (P = .063) similar to 
the PCR analysis. Mock mixed genotype controls comprised reads of 
the major and minor genotypes as expected; however, the actual per-
centages did not reflect the level of spike- in (0.1, 1.0 and 10%) of the 
minor genotypes and were lower than expected for gt1a (0.15, 0.03 
and 0.04%, respectively) but higher than expected for gt3 (0.58, 5.47 
and 47.57%, respectively) indicating that the PCR- NGS method was 
not quantitative.
Consensus sequences from the reads generated for the gt1a fidel-
ity controls showed 100%, 98.8% and 98.7% fidelity, with all errors 
detected in genome positions 1552- 1563. The gt3 transcripts were 
100% homologous to the original control sequence except in the re-
gion 1491- 1570 where there were several errors and a missing 30 bp 
region, likely the result of exclusion due to diminishing read quality at 
the ends of the reads.
The major genotypes identified by rt- PCR within the mixed infection 
samples were all identified as such by NGS, including sample G3- 85 that 
was originally diagnosed as gt3 but was identified in this study by rt- PCR 
and PCR as a gt1a major/gt3 minor sample. For the minor strains, the 
percentage of samples with normalised reads below the false- positive 
threshold was 36.9% (7 of 19). It is therefore unlikely that these sam-
ples would have been identified as mixed infections by PCR- NGS alone. 
There was no correlation (R2 = 0.0013, data not shown) between the per-
centage of normalised reads of the minor strains and their percentage 
within the total viral load ascertained by rt- PCR. The overall percentage 
of individuals with mixed infection in this subset of samples was similar 
for the NGS and PCR methods (36.2% and 34.5%, respectively), and the 
percentage of agreement between the methods was 72.4%. The number 
of samples testing positive for mixed infection by either NGS or PCR was 
48.3%. If the gold standard test is considered to be detection of mixed 
infection by either PCR or NGS, then PCR (67.9%) and NGS (60.7%) had 
similar sensitivities. However, the subset used for the NGS consists of 
all the mixed infection samples detected by PCR19 and only a small pro-
portion of the samples testing negative for mixed infection by PCR (39 
of 487). Proportionally, the expected percentage of mixed infections by 
NGS from 506 samples is 24.4% ([(11 + [(9/39) × (506- 19)])/506] × 100). 
In this instance, sensitivity of the NGS method in terms of the gold stan-
dard is 91.8%, whereas the PCR assay is only 14.5%.
A consensus of the NGS reads for each sample was compared phylo-
genetically to the Sanger sequences (Figure 2). Of the major genotypes, 
18 of 20 NGS consensus sequences were identical or highly similar to the 
Sanger sequences. Considerable heterogeneity was observed between 
sequences obtained by the two methods for the other two samples (G1a- 
92 and E- 15). There was little correlation between the minor genotype 
sequences produced by Sanger and NGS methods, with just 2 of 15 
minor strain sequences (G1a- 128 and E- 49) clustering.
4  | DISCUSSION
In this study, a genotype- specific nested PCR targeting the E1- E2 
region was developed and used to screen HCV- positive samples for 
the presence of mixed gt1a/gt3 infections. The mixed genotype infec-
tion prevalence rate in a cohort of 506 HCV- positive individuals from 
Scotland previously diagnosed with either gt1a or gt3 infection was 
3.8%. The nested PCR assay proved to be both sensitive and highly 
specific at the subgenotype level, capable of detecting low- level sec-
ondary infecting genotypes in a high background of the major geno-
type. The E1- E2 region is infrequently used for mixed HCV genotype 
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screening except as part of a fragment >1000 bp in length,25 with the 
5′ UTR and core regions being favoured. Whilst these regions can be 
used effectively for genotyping, diversity restriction means they are 
not always suitable for subtyping viral strains.26 The relatively short 
E1- E2 region targeted in this study was highly discriminatory for gen-
otyping and subgenotyping, providing more information than current 
clinical testing protocols.
The rate of mixed HCV genotype infections identified by PCR 
in our cohort (3.8%) is similar to the low prevalence rates observed 
in studies with large cohort sizes.5,27 Studies involving smaller co-
horts1,28,29 tend to have greater rates of HCV coinfection prevalence. 
The stringent focus on gt1a and gt3 may have contributed to the low 
prevalence rates observed. Gt1a and gt3 are the most common gen-
otypes within the UK and are estimated to be responsible for 90% of 
all HCV infections.30 As mixed genotype infections involving a wide 
range of different genotypes have been documented,31,32 the true 
prevalence of mixed genotype infection may be higher if all genotypes 
were analysed. However, no other genotypes were detected in our 
samples by PCR- NGS, therefore it is unlikely that any such increase in 
prevalence would be substantial. A large proportion of the individuals 
within our cohort had a known history of injecting drug use which 
entails a significantly higher exposure to multiple HCV challenges than 
other routes of HCV infection.1,29,32 Recent studies have also indicated 
that there may be a higher prevalence of superinfection and reinfec-
tion occurring within populations of PWID than is currently estimated 
and that factors such as long testing intervals and rapid viral clearance 
are hindering detection.33-35 Most patients provided a single sample 
giving a snapshot of the course of the infection. As HCV viral loads 
in chronically infected individuals can fluctuate substantially over 
the course of infection,1,31 the relative proportions of genotypes in 
a coinfection may not be static and multiple genotype infections can 
be transitory in nature.36,37 Diagnostically, it is difficult to differenti-
ate between acute and chronic infection and it is therefore unclear if 
 either genotype within the mixed infections of this cohort is transitory 
or if both genotypes had established chronic infections. The latter sit-
uation is more likely as most of our cohort were unlikely to be actively 
injecting drugs at the time of sampling; the average age of subjects 
within our cohort was 42.6 ± 9.8 years, the average age at which in-
jecting habits develop are 21- 22 years of age 38,39 and the average 
injecting career length has been estimated to be 8 years.40
The genotype- specific rt- PCR assay was less efficacious than the 
nested PCR for the mixed infection samples, quantifying only 75% of 
the minor genotypes. The use of a non- nested protocol may explain 
the reduced sensitivity of the rt- PCR protocol compared to the screen-
ing assay; however, the assays displayed similar sensitivities with con-
trol samples. Alternatively, the rt- PCR specificity at the subgenotype 
level may account for the discrepancies. It is notable, however, that 
most of the samples where the minor genotype was not detected by 
rt- PCR were of older origin and had undergone several freeze- thaw 
cycles following PCR screening, potentially affecting RNA yield.
Results from the genotype- specific rt- PCR assay indicated the 
HCV population structure comprised a major and a minor genotype. 
A significantly greater rate of mixed infection was determined in in-
dividuals diagnosed with gt3 than in patients diagnosed with gt1a. 
The disproportionate rate of individuals clinically diagnosed with gt3 
infections with mixed infections could suggest a difference in sensi-
tivity between the two genotypic rt- PCR assays; however, this was 
not apparent when quantifying the transcript controls in mock mixed 
Sample
Gt 3 VL 
(copies/μL)
Gt 1a VL 
(copies/
μL) % gt3a % gt1a
Major 
genotypea
Clinical 
genotypeb
G- 27 5878 9.44 99.84 0.16 3 3
G45 393 10.65 97.36 2.64 3 3
G3- 36 27064.79 13.2 99.95 0.05 3 3
G3- 41 15479.58 19.75 99.87 0.13 3 3
G3- 67 34198.66 71.75 99.79 0.21 3 3
G3- 73 1020.66 265.27 79.37 20.63 3 3
G3- 80 30.24 3.55 89.49 10.51 3 3
G3- 85 9.92 2781.49 0.36 99.64 1a 3
G3- 125 627.31 44.37 93.39 6.61 3 3
G3- 128 20448.3 6.85 99.97 0.03 3 3
G3- 155 12557.81 2.75 99.98 0.02 3 3
G3- 166 44811.86 13.25 99.97 0.03 3 3
G3- 176 763.48 1.67 99.78 0.22 3 3
G1a- 92 55.69 13363.43 0.42 99.58 1a 1a
G1a- 128 71.79 967.27 6.91 93.09 1a 1a
VL, viral load.
aMajor genotype as determined in this study.
bInfecting genotype determined clinically.
TABLE  2 Viral loads of gt1a and gt3 in 
mixed genotype infections
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TABLE  3 PCR- NGS Gt1a and Gt3 reads
Sample name Total no. of readsa Total no. of E1- E2 reads Normalised Gt1a reads (%)b
Normalised Gt3 
reads (%)b
Mixed infections
G3- 36 763 960 168 114 0.0268 99.9732
G3- 41 516 764 198 175 0.5707 99.4293
G3- 44 539 726 229 862 0.0009 99.9991
G3- 51 560 912 185 930 3.5879 96.4121
G3- 67 515 456 140 949 0.0021 99.9979
G3- 73 804 876 391 168 0.0013 99.9987
G3- 80 681 740 47 351 0.0169 99.9831
G3- 128 559 940 161 272 0.4266 99.5734
G3- 155 526 418 160 504 0.0019 99.9981
G3- 166 528 010 154 295 0.2664 99.7336
G3- 176 597 822 347 419 17.5045 82.4955
E- 15 248 034 23 641 99.6447 0.3553
E- 49 587 092 123 546 0.6054 99.3946
G- 27 628 534 110 341 0.3471 99.6529
G- 30 642 162 184 349 0.0016 99.9984
G- 45 631 746 121 395 0.0025 99.9975
G1a- 128 413 560 371 392 90.1118 9.8882
G3- 85 633 624 346 956 99.9983 0.0017
G1a- 92 994 070 318 881 96.1403 3.8597
Gt1a mono- infections
E1a- 1 435 000 368 351 99.9240 0.0760
E1a- 2 394 130 296 101 99.9983 0.0017
E1a- 3 239 416 215 405 99.9986 0.0014
E1a- 4 282 276 257 764 99.9977 0.0023
E1a- 5 476 342 419 911 100.0000 0.0000
E1a- 6 351 616 314 002 100.0000 0.0000
E1a- 7 442 038 384 902 99.9964 0.0036
E1a- 8 491 074 393 892 100.0000 0.0000
E1a- 9 683 040 608 478 100.0000 0.0000
E1a- 10 512 770 432 815 100.0000 0.0000
E1a- 11 475 102 426 133 99.9991 0.0009
E1a- 12 264 866 236 048 99.9992 0.0008
E1a- 13 388 436 338 405 99.9994 0.0006
E1a- 14 320 212 291 889 99.9425 0.0575
E1a- 15 513 908 429 738 99.9998 0.0002
E1a- 16 670 778 591 941 99.9976 0.0024
E1a- 17 895 712 825 765 100.0000 0.0000
E1a- 18 1221 904 686 278 99.9985 0.0015
E1a- 20 366 268 338 870 99.9988 0.0012
Gt3 mono- infections
G3- 18 512 136 232 372 0.2780 99.7220
G3- 29 432 544 167 388 0.0125 99.9875
G3- 35 924 612 254 339 0.0712 99.9288
G3- 42 286 708 74 476 0.0081 99.9919
(Continues)
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genotype infections. Alternatively, the primers used to amplify gt3 
may not have sufficient broad coverage of the genotype. This seems 
unlikely as all of the mono- infected gt3 strains were amplified, and 
there is no evidence that a large proportion of gt3 infections are 
currently undiagnosed, which would occur if this were the case. We 
cannot discount, however, that gt3 strains involved in mixed infec-
tions are phylogenetically divergent from mono- infection strains 
and have poor primer coverage. Gt1 infections can be more difficult 
to treat with non- DAA treatments than other HCV genotypes,41,42 
and as 28.2% of individuals in our study had been previously treated 
without achieving an SVR, there may have been partial resolution of 
coinfecting genotypes11,43 in some treated individuals which has dis-
proportionally resolved gt3 minor strains. The rate of infection among 
drug users who are already anti- HCV positive is lower than individuals 
previously unexposed, suggesting there may be some form of partial 
immunity,44,45 and it is possible that some genotypes confer a broader 
cross- protective immunity than others. Minority HCV strains within a 
superinfection may survive by replicating within extrahepatic sites,46 
and there may be genotypical differences in ability to adapt for sur-
vival in these regions. The reasons for the disparity in coinfecting rates 
of the genotypes are likely highly complex and involve a combination 
of genotype- specific host response31 and viral competition.
Sample name Total no. of readsa Total no. of E1- E2 reads Normalised Gt1a reads (%)b
Normalised Gt3 
reads (%)b
G3- 52 300 126 148 141 0.0007 99.9993
G3- 60 412 372 148 750 1.2208 98.7792
G3- 71 394 83 0 100
G3- 82 760 394 358 909 0.0014 99.9986
G3- 95 330 494 272 688 0.0238 99.9762
G3- 109 225 504 146 349 1.4930 98.5070
G3- 116 249 434 171 528 0.0006 99.9994
G3- 127 303 750 80 229 0 100
G3- 136 829 362 164 982 0.1109 99.8891
G3- 146 264 382 226 372 0.0009 99.9991
G3- 153 289 978 249 355 0.0056 99.9944
G3- 164 226 114 180 287 0.0011 99.9989
G3- 188 170 946 157 875 0.0215 99.9785
G3- 191 270 718 232 103 0.0009 99.9991
G3- 209 282 206 253 599 0.0016 99.9984
G3- 218 234 550 218 379 0 100
Controls
Gt1a- T1 1277 280 312 285 100 0
Gt1a- T2 1302 070 302 439 100 0
Gt1a- T3 1276 906 231 925 99.9987 0.0013
Gt1a- Hc 391 078 52 645 99.9506 0.0494
Gt1a- Mc 360 610 60 130 99.9684 0.0316
Gt1a- Lc 279 626 7328 99.8499 0.1501
Gt3- T1 745 546 191 069 0.0063 99.9937
Gt3- T2 553 894 121 431 0.0066 99.9934
Gt3- T3 713 904 103 927 0.0048 99.9952
Gt3- Hc 6042 524 2276 655 47.5672 52.4328
Gt3- Mc 402 494 122 609 5.4686 94.5314
Gt3- Lc 174 596 43 101 0.5824 99.4176
Serum neg.1d 667 952 72 0.0006 0.0102
Serum neg.2d 472 938 101 0.0214 0
aThe total number of paired- end reads per sample.
bThe number of reads for each genotype was normalised to the total number of E1- E2 reads.
cGt1a or Gt3a clonal transcripts with spiked- in controls of the opposite genotype constituting 10% (H), 1% (M) or 0.1% (L) of the total amount (106 copies/
μL).
dSera derived from individuals tested negative for HCV. Normalisation was performed against the total number of reads.
TABLE  3  (Continued)
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F I G U R E  2 Maximum likelihood phylogenetic tree comparing A, gt1a sequences (red) and B, gt3 sequences (blue) sequences of mixed 
infection samples obtained by Sanger sequencing and consensus sequences from deep sequencing. Labels with the suffix.ds are the NGS 
consensus sequences. Control strains are underlined, and samples without a corresponding consensus sequence from deep sequencing are 
shown in red. Sequences from the same sample that cluster are highlighted in yellow, and those sequence pairs not clustering are highlighted in 
grey. Circles denote major strains (as determined by rt- PCR). Bootstrap support of >70% after 1000 replicates is shown
(A) (B)
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A pan- genotypic primer set developed for the PCR- NGS proved 
to be highly effective at amplifying and typing gt1, gt2, gt3 and 
gt4 strains and one gt6a isolate at the subgenotype level. Despite 
this, no genotypes other than gt1a and gt3 were detected with the 
exception of assumed contaminant gt2 strains which were highly 
similar to a replicon strain used locally. To ascertain the suitabil-
ity of this assay for clinical diagnostics, it would be necessary to 
test the primers against gt5 and gt7 as well as more gt3 and gt6 
subtypes. Data collected during assay optimisation suggested that 
the primers could function effectively with at least two known 
mismatches.
PCR- based deep sequencing was selected in preference to 
metagenomic methods as the low ratio of HCV to human RNA af-
fects the sensitivity of the latter method. HCV has been detected 
in clinical samples by metagenomic methods at levels as low as 
2000 IU/mL47; however, this is still substantially less sensitive 
than would be required to detect most minor strains we identi-
fied by PCR. Sequencing errors and PCR bias can be problematic 
in PCR- NGS. The sequencing errors we identified using fidelity 
controls were restricted to the centre of sequences, equating 
to the end of reads in paired- end sequencing, where sequence 
quality often deteriorates. This issue could be easily resolved 
using an Illumina 500 cycle format. The PCR bias we observed, as 
demonstrated by poor agreement between minor strain propor-
tions and read numbers in mock mixed infections, indicates that 
the assay cannot be used for quantification. Rates of frequency 
can be distorted by margins of up to 100- fold relative to the true 
frequency.48,49
For the sample subset that was deep sequenced, the percentage 
of mixed infections were similar between the methods and, in com-
parison with detection by either PCR or NGS which we designated 
as the gold standard, the individual methods had similar sensitivities. 
However, an estimate of the expected percentage in the original sam-
ple set suggested a mixed infection prevalence rate of 24.4% by PCR- 
NGS, much greater than the rate calculated from PCR analysis (3.8%). 
A key issue in interpreting NGS data for viral diagnostics lies in defin-
ing background contamination. We applied a false- positive threshold 
based on background reads obtained in negative controls. However, 
there is uncertainty as to the reliability of such methods for PCR- NGS 
which has been shown to be poorly quantitative, in this study by in-
accurate read proportions obtained from mock mixed infections, and 
elsewhere.47-49 Reduction in PCR cycles may improve the quantitative 
aspect of PCR- NGS.
In conclusion, the prevalence rate of mixed infection in this UK 
cohort of 506 individuals by PCR was 3.8%, with gt3 as the major gen-
otype in most samples. The mixed infection rate obtained from PCR- 
NGS data was much higher; however, interpretation is hampered by 
the designation of false- positive thresholds with a technique that is 
poorly quantitative.
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